|
End-of-day quote
Shanghai S.E.
06/11/2026
|
5-day change | 1st Jan Change | ||
| 6.850 CNY | -3.25% |
|
-3.52% | +5.55% |
| Market Cap | 4.74B 710M 637M 582M 531M 1B 66.72B 1.03B 7.01B 2.8B 35.6B 2.66B 2.61B 112B | P/E 2024 |
18.1x | P/E 2025 | 14.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.96B 592M 531M 486M 443M 835M 55.68B 861M 5.85B 2.33B 29.71B 2.22B 2.18B 93.79B | EV / Sales 2024 |
1.45x | EV / Sales 2025 | 1.65x |
| Free-Float |
79.74% | Yield 2024 |
4.93% | Yield 2025 | 5.39% |
| 1 day | -3.25% | ||
| 1 week | -3.52% | ||
| Current month | -4.33% | ||
| 1 month | +0.44% | ||
| 3 months | +1.33% | ||
| 6 months | -3.25% | ||
| Current year | +5.55% |
| 1 week | 6.78 |  | 7.23 |
| 1 month | 6.52 | | 7.29 |
| Current year | 5.6 | | 7.45 |
| 1 year | 5.6 | | 7.45 |
| 3 years | 4.94 | | 8.68 |
| 5 years | 4.94 | | 11.9 |
| 10 years | 4.5 | | 11.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Wei Ren
CEO | Chief Executive Officer | 42 | 23/04/2019 |
Zhe Feng Zuo
DFI | Director of Finance/CFO | 54 | 17/05/2017 |
Peng Bo Ren
PRN | Corporate Officer/Principal | 53 | 11/03/2007 |
| Director | Title | Age | Since |
|---|---|---|---|
Wu Xian Ren
CHM | Chairman | 66 | 26/05/2005 |
Peng Bo Ren
BRD | Director/Board Member | 53 | 15/05/2014 |
Wei Ren
BRD | Director/Board Member | 42 | 23/04/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.25% | -3.52% | +0.29% | -7.31% | 734M | |
| -0.79% | -4.48% | +44.44% | +127.49% | 1,216B | |
| +1.43% | +1.11% | +47.73% | +82.08% | 656B | |
| +1.07% | -1.21% | +32.99% | +106.31% | 509B | |
| -0.36% | -2.84% | +47.23% | +64.51% | 384B | |
| -0.14% | -1.87% | +71.05% | +40.63% | 362B | |
| -0.78% | +0.59% | +31.01% | +59.68% | 311B | |
| -0.80% | +6.73% | +11.89% | +35.64% | 293B | |
| +0.03% | -1.20% | +45.89% | +68.76% | 249B | |
| -0.41% | -2.22% | +35.24% | +105.68% | 208B | |
| Average | -0.49% | +0.16% | +36.78% | +68.35% | 418.85B | |
| Weighted average by Cap. | -0.15% | +0.03% | +42.46% | +88.46% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 2.69B 402M 361M 330M 301M 567M 37.81B 585M 3.97B 1.58B 20.17B 1.51B 1.48B 63.69B | 2.24B 335M 301M 275M 251M 473M 31.53B 488M 3.31B 1.32B 16.82B 1.26B 1.23B 53.11B |
| Net income | 243M 36.34M 32.59M 29.79M 27.19M 51.23M 3.42B 52.85M 359M 143M 1.82B 136M 133M 5.75B | 320M 47.92M 42.98M 39.28M 35.85M 67.55M 4.5B 69.68M 473M 189M 2.4B 180M 176M 7.59B |
| Net Debt | -483M -72.31M -64.85M -59.27M -54.1M -102M -6.8B -105M -714M -285M -3.63B -271M -266M -11.45B | -784M -117M -105M -96.27M -87.88M -166M -11.04B -171M -1.16B -463M -5.89B -441M -431M -18.6B |
Employees
3,415
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/11/26 | CN¥6.850 | -3.25% | 34,054,700 |
| 05/11/26 | CN¥7.080 | +0.57% | 31,935,500 |
| 04/11/26 | CN¥7.040 | +0.72% | 33,283,097 |
| 03/11/26 | CN¥6.990 | -1.83% | 32,094,159 |
| 02/11/26 | CN¥7.120 | -0.56% | 36,153,573 |
- Stock Market
- Stocks
- 600351 Stock
Select your edition
All financial news and data tailored to specific country editions
